CN105273084B - Target the humanization modified non-internalization single-chain antibody P2h2 and application of HER2 - Google Patents
Target the humanization modified non-internalization single-chain antibody P2h2 and application of HER2 Download PDFInfo
- Publication number
- CN105273084B CN105273084B CN201510622153.4A CN201510622153A CN105273084B CN 105273084 B CN105273084 B CN 105273084B CN 201510622153 A CN201510622153 A CN 201510622153A CN 105273084 B CN105273084 B CN 105273084B
- Authority
- CN
- China
- Prior art keywords
- antibody
- chain antibody
- her2
- internalization
- e23sfv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Peptides Or Proteins (AREA)
Abstract
The invention discloses a kind of humanization modified non-internalization single-chain antibody P2h2 and application of targeting HER2, belong to antitumor technical field.Humanization modified non-internalization single-chain antibody P2h2 disclosed by the invention, amino acid sequence is as shown in SEQ.ID.NO.1；The acquisition of the antibody is that the CDR of mouse single-chain antibody e23sFv is transplanted to the FR of the highest human antibody consensus sequence of homology, to be reselection the mouse amino acid residue in e23sFv to maintaining 13 important amino acid residue mutations of antibody space conformation in FR, structure storage capacity is 213Single chain antibody phage shows library, and filtering out 1 plant has the high affine active non-internalization single-chain antibody P2h2 of humanization, lays a solid foundation for the application in clinical diagnosis and therapy field.
Description
Technical field
The invention belongs to antitumor technical fields, are related to a kind of anti-human HER2 single-chain antibodies, more particularly to a kind of through people source
Change the anti-human HER2 single-chain antibodies of non-internalization of transformation, including its amino acid sequence and nucleotide sequence and preparation method for antibody and
Its diagnosis and treatment purposes to HER2 positive tumor cells.
Background technology
HER2 (human epidermal growth factor receptor-2, ErbB2/P185) is human epidermal growth
Second member of factor acceptor (EGFR) family, is encoded by proto-oncogene erbB2/Her2, and encoding gene is positioned at people's dyeing
Body 17q21, molecular weight 185kDa are a kind of tyrosine kinase receptor membrane glycoproteins.HER2 by with HER1, HER3 or HER4
Heterodimer is formed, the signal paths such as downstream MAPK and PI3K is caused to activate, growth signals is excessively conducted and is disliked so as to cause cell
Property proliferation.In mankind's kinds of tumors, including 25-30% breast cancer, 35-45% cancers of pancreas and 90% colorectal cancer, 16-
57% non-small cell lung cancer, gastric cancer of 9-38% etc. have had been found that the amplification of HER2 proto-oncogenes or protein overexpression phenomenon,
Clinically it is known as HER2 positive tumors, is mainly shown as malignancy height, easily progress and transfer, it is insensitive to chemicotherapy,
Easily recurrence, patient survival are short.
1975, Kohler and Milstein invented for prepare monoclonal antibody (Monoclonal antibody,
MAb hybridoma technology), later monoclonal antibody medicine rapidly develop and be applied to clinic.In recent years, the antibody drug of HER2 is targeted
Have become HER2 positive tumors and treats new hot spot.Herceptin (herceptin, English name Trastuzumab/Herceptin)
It is the anti-HER 2 humanized monoclonal antibody drug of Genetech companies exploitation, U.S. FDA is bent at present in approval listing in 1998
Trastuzumab combined chemotherapy drug (taxol etc.) has become HER2 and is overexpressed advanced breast cancer and late gastric cancer
First-line treatment scheme, in the treatment of HER2 positive metastatic breast cancer, up to 38%, European EMEA has been criticized clinical effective rate
First-line treatment scheme of the quasi- Trastuzumab combined chemotherapies drug as treatment HER2 positive advanced gastric carcinomas.
Although Trastuzumab clinical application achieve it is encouraging as a result, have a large amount of patients to treat nothing
It is recurred after reaction, or treatment.Studies have reported that mouse monoclonal antibody, which is applied to the mankind, stronger immunogenicity, body can be caused to exempt from
Epidemic disease system to the immunological rejection of the foreign protei, generate human anti-mouse antibody (Human anti-mouse antibody,
HAMA it) reacts, the anaphylactic shock of serious patient can be even caused when reuse.And due to the presence of HAMA, mouse monoclonal antibody
It can be removed quickly in human body, half-life period is very short, therefore limits its clinical application.Trastuzumab is chimeric for people mouse
Antibody, but its variable region portion is mouse, can cause human body and generate HAMA, there is metastatic breast cancer prolonged application
The research report of Trastuzumab treatments points out that cardiac toxic occurred in about 25% patient；Third stage test result
Show that HER2 positive breast cancer patients only have about 1/3 pair of Trastuzumab single-dose treatment to have definite curative effect；In clinic, i.e.,
Make combined chemotherapy, most patient just will produce drug resistance being treated in 1 year using Trastuzumab.
As relationship is understood in depth between all kinds of antibody structures and function, antibody engineering technical antagonism body structure is utilized
It is transformed, by the monoclonal antibody human source (Monoclonal humanization) of animal origin, to reduce these monoclonal antibodies
The immunogenicity for being applied to generate after human body repeatedly is allowed to the treatment for human diseases, is the hot spot studied at present.It is anti-
The humanization modified main policies of body have following several：
1. chimeric antibody
The constant region of antibody is the strongest position of immunogenicity in antibody molecule structure, with technique for gene engineering that mouse is single
Anti- variable region and the constant region of human antibody are mutually spliced, and simplest form people/mouse chimeric antibody of mouse monoclonal antibody humanization is become
(chimeric antiboay).Chimeric antibody greatly reduces the immunogenicity of mouse source monoclonal antibody, while remaining mouse monoclonal antibody again
Compatibility and specificity.Since chimeric antibody still remains the mouse source sequence of original mouse source antibody about 30% or so, immunogene
Though property decreases, but still different degrees of HAMA can be caused to react.
2. the humanized antibody of complementary determining region (complementary determining region, CDR) transplanting
The light and heavy chain variable region of each antibody molecule Fab section respectively have 3 antigen complementary determining regions (CDR1, CDR2 and
CDR3), there is the framework region (framework region, FR) that stable structure acts between them, CDR can be in direct contact anti-
Original determines the specificity of antibody, its three-dimensional conformation is extremely conservative as the holder of support CDR by FR.CDR grafted antibody is mouse list
Anti- complementary determining region (CDR) is transplanted to the built-up antibody of skeleton area FR of people's monoclonal antibody, clinical tests prove that, it is immunized
Originality is significantly reduced.
3. the reconstruct of people source FR templates
1. template replace, in existing antibody sequence library search with mouse mAb FR have the people source FR of maximum homology to
It replaces.Light and heavy chain can make have better homology between mouse source CDR and people's template in this way usually from different human antibodies.Ying Jiang
The amino acid residue closely related with CDR is retained in the people source FR of replacement in mouse FR.In order to keep the space conformation of CDR,
Pay special attention to the residue around accumulation residue and the CDR below original antibodies CDR.2. Compensation Transformation, Compensation Transformation can be recognized
There to be interaction with CDR in people's FR selections to be the further extension that template is replaced, have close pass with affinity of antibody
System or the residue to play a crucial role to the folding of FR space structures are changed, and are transplanted with compensating complete CDR.3. positioning retains, most
Simple situation template (minimal positional template) can confirm which position is to maintain antibody in antibody variable region
Antigen-binding domains integrality necessary to, selection for humanization people FR when, first from existing human antibody
It is searched in conserved sequence and sequence most like mouse FR；Secondly determine that the key position of mouse variable region is residual according to most simple situation template
Base；Finally retain all these positions and by rest part humanization.
4. surface is remolded
The amino acid residue in the inhuman source in non-Human monoclonal antibody variable region (Fv) surface is replaced with to the amino acid residue of humanized,
The surface humanization for making the areas non-human source antibodies Fv, reduces its immunogenicity, while not influencing the overall space conformation in the areas Fv, to
Retain the structure of its antigen-binding site.
5. epitope M8003 line (epitope-guided selection)
The light chain of mouse antibody or heavy chain library and the heavy chain or light chain libraries of human antibody are matched, are built into that " one mouse of people is miscellaneous
Conjunction antibody library ", the clone of screening and antigen binding, separation obtain the heavy chain or light chain gene of human antibody, then by them with people's
Light chain or heavy chain library mixing, with antigen selection, can obtain the human antibodies specific with antigen binding.
Invention content
The purpose of the present invention is to provide the humanization modified non-internalization single-chain antibody P2h2 of targeting HER2 a kind of and answer
With.
The humanization modified non-internalization single-chain antibody P2h2 of targeting HER2 disclosed by the invention a kind of, amino acid sequence
As shown in SEQ.ID.NO.1.
Encode the nucleotide sequence of humanization modified non-internalization single-chain antibody P2h2 of above-mentioned targeting HER2 such as
Shown in SEQ.ID.NO.2.
The invention also discloses the humanization modified non-internalization single-chain antibody P2h2 of above-mentioned targeting HER2 to prepare anti-swell
It is prepared by the application in tumor medicine and/or health products, and the humanization modified non-internalization single-chain antibody P2h2 of targeting HER2
Application in HER2 positive tumor diagnostic reagents.
The drug and/or health products is the drug and/or health products of anti-HER2 positive tumor cells.
The HER2 positive tumor cells are that breast cancer cell, stomach cancer cell, non-small cell lung cancer cell or oophoroma are thin
Born of the same parents etc..
Compared with prior art, the present invention has technique effect beneficial below：
1, present invention HER2 single-chain antibodies e23sFv anti-human to mouse for the first time has been carried out humanization modified, and e23 is HER2
Affinity and the clone for inhibiting tumour efficiency best in the hybridoma prepared after mouse is immunized in molecule extracellular fragment, to the single-stranded of e23
The humanization modified of antibody formation e23sFv still belongs to the first time.
2, it will be replaced with the FR of the highest human antibody consensus sequence FR and e23sFv of VL, VH homology of e23sFv
It changes, while selecting 13 sites FR to play an important role to antibody conformation, the amino acid residue of original e23sFv is sported, with most
Limits ensure the correct folding of single-chain antibody conformation.
3, structure storage capacity is 213Mutant single-chain antibody library, filtered out using display technique of bacteriophage affine to HER2
The high Humanized single chain antibody strain P2h2 of power ensures can there is higher affinity by humanization modified single-chain antibody.
4, it is verified through humanization modified P2h2 to HER2 molecules from molecule to cellular level using kinds of experiments means
Affine activity and whether there is internalization activity, compares the size of itself and mouse source single-chain antibody e23sFv immunogenicities, it is ensured that last
The molecule of screening has higher affine activity and lower immunogenicity, and the antitumor diagnosis and treatment of HER2 are targeted for further research and development
New strategy lays the foundation.
Description of the drawings
Fig. 1 is that full-length human single-chain antibody hue23sFv amino acid sequences build flow diagram；
Fig. 2 is the mutant primer sequence results of Humanized single chain antibody mutant；
Fig. 3 is multisite mutation PCR Gel electrophoresis results figures；
Fig. 4 is the structure and 4 wheel elutriation result figures of humanization single chain antibody phage antibody library；
Fig. 5 is that Phage ELISA screen the highest single-chain antibody strain result of affinity；
Fig. 6 is the prokaryotic expression and purification result of 4 plants of Humanized single chain antibodies；
Fig. 7 is that SPR measures Humanized single chain antibody to recombined human HER2 molecule affinity costants；
Wherein (a) is affinity costant KD 4.512*10s of the e23sFv to recombined human HER2 molecules-8M；(b) it is P2h2 counterweights
The affinity costant KD1.559*10 of group people's HER2 molecules-9M；(c) be e23sFv, P1h2, P1h3, P2h2, P2h5 to recombined human
The combination dissociation capability of HER2 molecules is distributed.
Fig. 8 is the affine activity that ELISA measures Humanized single chain antibody to recombined human HER2 molecules；
Fig. 9 is the specificity that Flow cytometry Humanized single chain antibody combines HER2 positive tumor cells；
Figure 10 is that laser confocal microscope detects Humanized single chain antibody internalization into HER2 positive tumor cell activity；
Wherein, (a) is that e23sFv, P2h2 internalization enter HER2 positive breast cancer cells BT-474；Be (b) e23sFv,
P2h2 internalizations enter HER2 positive ovarian cancer cells SKOV-3；(c) it cannot be internalized by into HER2 negative breasts for e23sFv, P2h2
Cancer cell MCF-7.
Figure 11 is the level for stimulation human PBMC's generation IFN-γ that ELISPOT detects Humanized single chain antibody；
Figure 12 is human peripheral multiple cytokine detection evaluation Humanized single chain antibody immunogenicity result；
Wherein, (a) is the level that e23sFv, P1h2, P1h3, P2h2, P2h5 stimulate Healthy People PBMC TNF secretions-α；(b)
The level of Healthy People PBMC secretion of gamma-IFN is stimulated for e23sFv, P1h2, P1h3, P2h2, P2h5；Be (c) e23sFv, P1h2,
P1h3, P2h2, P2h5 stimulate the level of Healthy People PBMC secretions IL-10；(d) it is that e23sFv, P1h2, P1h3, P2h2, P2h5 are pierced
Swash the level of Healthy People PBMC secretions IL-2；(e) it is e23sFv, P1h2, P1h3, P2h2, P2h5 stimulation Healthy People PBMC secretions
The level of IL-4；(f) level for being e23sFv, P1h2, P1h3, P2h2, P2h5 stimulation Healthy People PBMC secretions IL-5；(g) it is
E23sFv, P1h2, P1h3, P2h2, P2h5 stimulate the level of Healthy People PBMC secretions IL-17a；Be (h) e23sFv, P1h2,
P1h3, P2h2, P2h5 stimulate the level of Healthy People PBMC secretions IL-21.
Specific embodiment：
One, the structure of Humanized single chain antibody and its mutant bacteriophage antibody library
1, the determination of Humanized single chain antibody sequence
The light chain variable region of e23sFv is subjected to BLAST, is found and the highest human antibody light variable region of its homology
Sequence, with the framework region (FR) of the affiliated subclass consensus sequence in this human antibody light variable region (concensus sequence)
The FR for replacing e23sFv, builds the light chain huVL of full-length human.The replacement of same procedure, structure are carried out to the heavy chain of e23sFv
The heavy chain huVH of full-length human, and connect with Linker with huVL, the hue23sFv of full-length human is built, as shown in Figure 1.
2, the determination of Humanized single chain antibody mutant sequence
E. coli codon optimization is carried out to the gene order of hue23sFv, full genome synthesis is built into pUC19 carriers
In.13 sites that antibody structure plays an important role will be respectively synthesized using the method for multipoint mutation in the FR of hue23sFv
Mutant primer, mutant primer sequence are as shown in Figure 2.It is each using Multi-site directed mutation kit (Takara)
A amino acid residue for sporting original mouse source, structure 213A mutant, as shown in Figure 3.
3, the structure of Humanized single chain antibody mutant bacteriophage antibody library
Using Sfi I and Not I as restriction enzyme site, hue23sFv and mutant digestion are connected into pCANTAB5E bacteriophages
Carrier, Electroporation-competent cells TG1 after being transferred to 2*YTAG culture medium amplification cultivations to exponential phase, are added auxiliary and bite
Thalline M13K07 infects 1h, and centrifugation is abandoned supernatant, is resuspended with 2*YTAK, 37 DEG C of overnight incubations, and collection supernatant, which is surface display, to be had
The phage library of single-chain antibody, it is 5*10 to measure its phage titre11CFU。
Two, the screening and identification of high-affinity Humanized single chain antibody
The phage antibody library of Humanized single chain antibody and 37 DEG C of elisa plate for being coated with HER2 molecules are incubated 2h altogether,
0.05%Tween20PBS is washed 5 times, and exponential phase TG1 bacterium solutions are added and are incubated 1h in 37 DEG C of slow shake, make in conjunction with HER2's
ScFv- bacteriophages infect TGI and are enriched with again.The bacterial cultures for having infected ScFv- bacteriophages is taken to measure titre, while with auxiliary
Secondary ScFv- phage libraries are prepared after helper phage M13K07 infection, carry out elutriation again, and be stepped up washing times, altogether
Four-wheel elutriation is carried out, the phage titre of often wheel elutriation input and output is measured and calculates yield, as shown in Figure 4.
ELISA Screening are carried out to the bacteriophage that is combined with HER2 after four-wheel screens, filter out 20 plants it is affine
Highest 4 plants of the higher phage antibody of power, wherein affinity is P1h2, P1h3, P2h2, P2h5 as shown in figure 5, P2h2 amino
Acid sequence is as shown in SEQ.ID.NO.1.
Three, the prokaryotic expression of Humanized single chain antibody, purifying and renaturation
4 plants of phage single-chain antibody sequences that elutriation obtains are cloned into former expression vector pET28a, 1mM IPTG inductions
It is expressed with inclusion bodies, inclusion body, through Ni-NTA affinitive layer purifications, is removed with slow dialysis and become with 6M GuCl denaturation
Property agent method make protein renaturation to obtain active single-chain antibody, SDS-PAGE detects single-chain antibody purity up to 90%
More than, as shown in Figure 6.
Four, surface plasma resonance technology (SPR) measures affinity of the Humanized single chain antibody to HER2 molecules
Affinity costant KD of the Humanized single chain antibody to HER2 molecules is measured using Biacore T100 (GE).CM5 chips
Coupling capture antibody anti human IgG (Fc) are further coated with recombined human HER2 albumen (Fc tag), prepare concentration respectively
For 32nM, 16nM, 8nM, 4nM, 2nM single-chain antibody as mobile phase, single cycle kinetics model measures itself and HER2 molecules
In conjunction with the size for causing response (RU), to calculate e23sFv and Humanized single chain antibody to HER2 affinity constants.Such as Fig. 7
It is shown, the affinity constant KD 4.512*10 of e23sFv-8The affinity constant of M, P2h2 are 1.559*10-9M, P2h2's is affine
Force constant is apparently higher than e23sFv.
Five, ELISA detects affine activity of the Humanized single chain antibody to cell surface HER2 molecules
96 orifice plates are spread with HER2 positive tumor cells BT-474, per hole cell number 1*104, 37 DEG C are cultivated for 24 hours, are abandoned in culture
Clearly, 4% paraformaldehyde room temperature fixes 20min, and 5% skimmed milk power room temperature closes 1h, and it is anti-that 3 times of doubling dilution Humanized single chains are added
Body, maximum concentration 3uM, 4 DEG C of overnight incubations, PBST are washed 6 times, are added 1:The primary antibody of 1000 diluted anti-His is incubated at room temperature 2h,
PBST is washed 6 times, is added 1:The secondary antibody of 2500 diluted HRP labels is incubated at room temperature 1h, and PBST is washed six times, TMB color development at room temperature
10min measures OD450 after color development stopping, as shown in figure 8, single-chain antibody P2h2 compared with mouse source e23sFv reach earlier plateau and
Platform numerical value bigger prompts P2h2 activity affine to HER2 molecules to be higher than e23sFv.
Six, the specificity that Flow cytometry Humanized single chain antibody combines HER2 positive tumor cells
Fluorescein Dylight 488 marks single-chain antibody respectively, and it is respectively e23sFv 73.3% to measure labeling effciency,
P1h274.6%, P1h372.1%, P2h273.8%, P2h575.2%.By fluorescein-labeled Humanized single chain antibody P2h2
It is incubated altogether with HER2 positive tumor cells BT-474 and SKOV-3 respectively, HER2 negative tumor cells MCF-7 is as negative control.
Simultaneously by unlabelled e23sFv with two kinds of different final concentrations (125nM, 250nM) and fluorescein-labeled Humanized single chain antibody
It being incubated with BT-474 and SKOV-3 after P2h2 mixing, on ice 1h, three times, 1000rpm/min is centrifuged streaming wash liquid,
500ulPBS is resuspended, upper machine testing.As shown in figure 9, P2h2 can be combined its right with the surfaces BT-474 and SKOV-3 HER2 molecules
The characteristics of combination of HER2 can be blocked by the e23sFv of various concentration, and dose-dependant is presented in blocking effect prompts
Compared with parent e23sFv significant change does not occur for the epitope of P2h2 combination HER2 molecules.
Seven, internalization activity of the laser confocal microscope detection Humanized single chain antibody to HER2 positive tumor cells
The cell climbing sheet for preparing HER2 positive tumor cells BT-474 and SKOV-3, exists with fluorescein-labeled single-chain antibody
37 DEG C are incubated 4h altogether, and each strain single-chain antibody internalization of confocal laser scanning microscope enters HER2 positive tumor cells after mounting
Activity, HER2 negative tumor cells MCF-7 is as negative control.As shown in Figure 10, BT-474 the and SKOV-3 born of the same parents that P2h2 is incubated
It inside has no apparent fluorescence distribution, prompts P2h2 that cannot be internalized by into HER2 positive tumor cells.
Eight, ELISPOT evaluates Humanized single chain antibody immunogenicity
12 healthy human peripheral bloods are taken, lymphocyte separation medium detaches mononuclearcell (PBMC), respectively with 3uM
For 24 hours in 37 DEG C of stimulations, ELISPOT detects PBMC secretion of gamma-IFN water by e23sFv, P1h2, P1h3, P2h2, P2h5 (PBS dilutions)
It is flat.As a result the positive cell frequency that prompt Humanized single chain antibody P2h2 stimulations PBMC generates IFN-γ has compared with parent e23sFv
It significantly reduces, difference has statistical significance, as shown in figure 11.
Nine, human peripheral cytokine profiles detection evaluation Humanized single chain antibody immunogenicity
12 healthy human peripheral bloods are taken, lymphocyte separation medium detaches mononuclearcell (PBMC), respectively with 3uM
E23sFv and Humanized single chain antibody P1h2, P1h3, P2h2, P2h5 are stimulated for 24 hours in 37 DEG C, collect cells and supernatant,
LEGEND plex kit measurement cell factors IL-2, IL-4, IL-5, IL-10, IL-17a, IL-21, IFN-γ, TNF-α are dense
Degree compares the variation of e23sFv and P1h2, P1h3, P2h2, P2h5 stimulation PBMC cytokine secretion amounts.As a result humanization is prompted
Single-chain antibody P2h2 stimulation PBMC generations IL-2, IL-10, TNF-α, the level of IFN-γ have compared with parent e23sFv obviously to be subtracted
It is few, it prompts after humanization modified, the ability that single-chain antibody P2h2 causes human body generation immune response is decreased obviously, difference tool
It is statistically significant, as shown in figure 12.
In conclusion the present invention provides a kind of non-internalization single-chain antibody P2h2 of humanization of targeting HER2, which obtains
Must be the FR that the CDR of mouse single-chain antibody e23sFv is transplanted to the highest human antibody consensus sequence of homology, reselection
Ground will be residual for the mouse amino acid in e23sFv to maintaining 13 important amino acid residue mutations of antibody space conformation in FR
Base, structure storage capacity are 213Single chain antibody phage shows library, and it is single-stranded to filter out the non-internalization of 1 plant of humanization with high-affinity
Antibody P2h2 lays a solid foundation for the application in clinical diagnosis and therapy field.
Claims (4)
1. a kind of humanization modified non-internalization single-chain antibody P2h2 of targeting HER2, which is characterized in that the humanization changes
The amino acid sequence of the non-internalization single-chain antibody P2h2 made is as shown in SEQ.ID.NO.1.
2. the humanization modified non-internalization single-chain antibody P2h2 of targeting HER2 as described in claim 1, which is characterized in that compile
The nucleotide sequence of the humanization modified non-internalization single-chain antibody P2h2 of code is as shown in SEQ.ID.NO.2.
3. humanization modified non-internalization single-chain antibody P2h2 application in preparations of anti-tumor drugs described in claim 1,
It is characterized in that, the tumour is HER2 positive tumors.
4. the humanization modified non-internalization single-chain antibody P2h2 of targeting HER2 described in claim 1 is swollen in the preparation HER2 positives
Application in tumor diagnostic reagent.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510622153.4A CN105273084B (en) | 2015-09-25 | 2015-09-25 | Target the humanization modified non-internalization single-chain antibody P2h2 and application of HER2 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510622153.4A CN105273084B (en) | 2015-09-25 | 2015-09-25 | Target the humanization modified non-internalization single-chain antibody P2h2 and application of HER2 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105273084A CN105273084A (en) | 2016-01-27 |
| CN105273084B true CN105273084B (en) | 2018-10-09 |
Family
ID=55142976
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510622153.4A Active CN105273084B (en) | 2015-09-25 | 2015-09-25 | Target the humanization modified non-internalization single-chain antibody P2h2 and application of HER2 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105273084B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109385430B (en) * | 2017-08-11 | 2022-03-25 | 华南理工大学 | HER2 fusion single-chain antibody, preparation method and application |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999056129A1 (en) * | 1998-04-24 | 1999-11-04 | The Regents Of The University Of California | Methods of selecting internalizing antibodies |
| CN101979594A (en) * | 2010-11-05 | 2011-02-23 | 中国人民解放军第四军医大学 | Influenza virus hemagglutinin fusion peptide-containing targeted recombinant molecule gene, protein encoded thereby and application thereof |
| CN103910799A (en) * | 2014-03-06 | 2014-07-09 | 中国人民解放军第四军医大学 | Fusion protein based on anti-EGFR single-chain antibody and arginine nonamer, and applications of fusion protein |
| CN104225594A (en) * | 2014-09-23 | 2014-12-24 | 合肥瀚科迈博生物技术有限公司 | HER2-resistant humanized antibody and relevant tumor-resistant composition thereof |
-
2015
- 2015-09-25 CN CN201510622153.4A patent/CN105273084B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999056129A1 (en) * | 1998-04-24 | 1999-11-04 | The Regents Of The University Of California | Methods of selecting internalizing antibodies |
| CN101979594A (en) * | 2010-11-05 | 2011-02-23 | 中国人民解放军第四军医大学 | Influenza virus hemagglutinin fusion peptide-containing targeted recombinant molecule gene, protein encoded thereby and application thereof |
| CN103910799A (en) * | 2014-03-06 | 2014-07-09 | 中国人民解放军第四军医大学 | Fusion protein based on anti-EGFR single-chain antibody and arginine nonamer, and applications of fusion protein |
| CN104225594A (en) * | 2014-09-23 | 2014-12-24 | 合肥瀚科迈博生物技术有限公司 | HER2-resistant humanized antibody and relevant tumor-resistant composition thereof |
Non-Patent Citations (2)
| Title |
|---|
| Single-Chain Antibody-Based Immunotoxins Targeting Her2/neu: Design Optimization and Impact of Affinity on Antitumor Efficacy and Off-Target Toxicity;Yu Cao等;《Molecular Cancer Therapeutics》;20111116;第11卷(第1期);第143-153页 * |
| Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis;Ulrik B等;《Biochimica et Biophysica Acta》;20021231;第1591卷;第109-118页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105273084A (en) | 2016-01-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107108747A (en) | Bispecific antibody or mixtures of antibodies with common light chain | |
| CN103987731B (en) | AGR2 blocking antibodies and application thereof | |
| JP7209464B2 (en) | Immunostimulatory monoclonal antibody against human interleukin-2 | |
| CN103030695B (en) | The pharmaceutical composition of anti-c Met humanized antibodies and the prevention containing it or treating cancer | |
| KR101739489B1 (en) | Fully human anti-human epidemic growth factor receptor antibodies and encoding genes and application of the antibodies | |
| CN102574919B (en) | Antibodies specifically binding to the epidermal growth factor receptor | |
| US9580498B2 (en) | Monoclonal antibody for antagonizing and inhibiting binding of vascular endothelial growth factor to its receptor, and coding sequence | |
| CN107840891A (en) | The anti-MSLN antibody of high-affinity and its application | |
| CN111744013B (en) | Methods and pharmaceutical combinations for treating diseases using anti-TIGIT antibodies in combination with PD-1 inhibitors | |
| CN104225594B (en) | Anti-HER 2 humanized antibody and relevant anti-tumor compositions thereof | |
| CN112513089A (en) | anti-CD 73 antibody, antigen binding fragment thereof and application | |
| US20230279115A1 (en) | Single variable domain antibody targeting human programmed death ligand 1 (pd-l1) and derivative thereof | |
| CN112243443B (en) | anti-TROP-2 antibodies, antigen-binding fragments thereof, and medical uses thereof | |
| CN116514971A (en) | anti-LAG-3 monoclonal antibody, antigen binding fragment thereof and application thereof | |
| CN114502591A (en) | Antibodies targeting BCMA, bispecific antibodies and uses thereof | |
| CN108178799A (en) | A kind of nano antibody of anti-CA 125 sugar antigen and its application | |
| CN105131117B (en) | The humanization modified of targeting HER2 is internalized by single-chain antibody P1h2 and application | |
| CN101701039B (en) | Variable regions of light chains and heavy chains of FMU-EPCAM-2A9 monoclonal antibodies | |
| CN113943371B (en) | anti-HER 2/anti-PD-L1 bifunctional antibody and application thereof | |
| CN102276722A (en) | Novel vascular endothelial growth factor humanized monoclonal antibody | |
| CN105273084B (en) | Target the humanization modified non-internalization single-chain antibody P2h2 and application of HER2 | |
| CN105131116B (en) | The humanization modified of targeting HER2 is internalized by single-chain antibody P1h3 and preparation method and application | |
| CN109071671A (en) | ERBB2 targeting antibodies | |
| CN103265631A (en) | Heavy chain and light chain variable regions of anti-human CRT monoclonal antibody | |
| CN116262786A (en) | Single-domain antibody aiming at FOLR1, derivative protein and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |